A significantly higher proportion of patients in the immunotherapy group than in the control group had an adverse event ( 62 % vs 41 % ; P = .002 ) , but the proportion of patients with serious adverse events did not differ significantly between groups ( 7.8 % vs 3.5 % ; P = .15 ) .